{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:50:54Z","timestamp":1782377454617,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is a leading global malignant tumor with poor prognosis. Immune checkpoint inhibitors (ICIs) have become a breakthrough treatment for HCC, but a systematic landscape analysis of global ICI clinical trials is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four international clinical trial databases were systematically searched up to February 14, 2026. After screening, 132 eligible trials were included and analyzed for geographic distribution, molecular targets, clinical phases, trial status and result publication rate using R 4.5.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trials displayed a China\u2013US dual-core pattern (95 vs. 16). PD-1\/PD-L1 inhibitors were the predominant targets, while CTLA-4 inhibitor trials were scarce. Phase II was the most frequent clinical phase (59 trials). Over 80% were interventional studies; most were recruiting or of unknown status, with only 6 terminated or withdrawn. The overall result publication rate was extremely low, with 71 PD1-targeting trials and 71.4% CTLA-4 trials were unpublished.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Global HCC ICIs trials are highly concentrated geographically and by target, with stable research progress. However, major challenges include low result translation efficiency, unbalanced target development, insufficient early\/late-phase trials and uneven global collaboration. Targeted optimization is needed to promote clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1831229","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:21:06Z","timestamp":1781068866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of immune checkpoint inhibitors in hepatocellular carcinoma: a landscape analysis of clinical trial databases"],"prefix":"10.3389","volume":"17","author":[{"given":"Junjie","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Emergency, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Lou","sequence":"additional","affiliation":[{"name":"Medical School of Ophthalmology & Optometry, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Imaging Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiquan","family":"Wen","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Emergency, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02370-2","article-title":"PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"Oncogene"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1850","article-title":"Molecular imaging of tumor microenvironment to assess the effects of locoregional treatment for hepatocellular carcinoma","volume":"6","author":"Chen","year":"2022","journal-title":"Hepatol Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1714314","article-title":"Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"Nejm Evid"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00967-4","article-title":"Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions","volume":"21","author":"Mak","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40164-025-00636-5","article-title":"Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential","volume":"14","author":"Tong","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0008","article-title":"Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials","volume":"14","author":"Harding","year":"2018","journal-title":"Future Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12885-023-11112-w","article-title":"Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis","volume":"23","author":"Gao","year":"2023","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20220624-00344","article-title":"Advances in targeted and immune therapies for hepatocellular carcinoma","volume":"30","author":"Nan","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.765101","article-title":"Immunotherapy for hepatocellular carcinoma: current status and future prospects","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000528272","article-title":"IMbrave150: Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04775-2","article-title":"A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma","volume":"149","author":"Zeng","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.06.01","article-title":"Liver cancer incidence and mortality in China: temporal trends and projections to 2030","volume":"30","author":"Zheng","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0156","article-title":"Publication of randomized clinical trials in pediatric research: a follow-up study","volume":"1","author":"Crockett","year":"2018","journal-title":"JAMA Netw Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta14080","article-title":"Dissemination and publication of research findings: an updated review of related biases","volume":"14","author":"Song","year":"2010","journal-title":"Health Technol Assess"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2026.112182","article-title":"Drug approvals in crowded drug classes potentially reflect efficacy overestimates and false positivity: a portfolio analysis of immune checkpoint inhibitor trials","volume":"193","author":"Carlisle","year":"2026","journal-title":"J Clin Epidemiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/neur.2020.0055","article-title":"Leveling the playing field: a new initiative to publish negative and replication data in brain trauma","volume":"1","author":"Ferland-Beckham","year":"2020","journal-title":"Neurotrauma Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41467-024-46118-w","article-title":"Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma","volume":"15","author":"He","year":"2024","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","article-title":"Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"biomark Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/mef2.70008","article-title":"The recent development, application, and future prospects of muscle atrophy animal models","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm - Future Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:36:43Z","timestamp":1782376603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1831229"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831229","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1831229"}}